Logo image of ABCL

ABCELLERA BIOLOGICS INC (ABCL) Stock Fundamental Analysis

NASDAQ:ABCL - Nasdaq - CA00288U1066 - Common Stock - Currency: USD

3.03  -0.11 (-3.5%)

Premarket: 3.03 0 (0%)

Fundamental Rating

4

Taking everything into account, ABCL scores 4 out of 10 in our fundamental rating. ABCL was compared to 56 industry peers in the Life Sciences Tools & Services industry. No worries on liquidiy or solvency for ABCL as it has an excellent financial health rating, but there are worries on the profitability. ABCL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ABCL had negative earnings in the past year.
In the past year ABCL has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: ABCL reported negative net income in multiple years.
ABCL had a positive operating cash flow in 4 of the past 5 years.
ABCL Yearly Net Income VS EBIT VS OCF VS FCFABCL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M -200M

1.2 Ratios

ABCL has a Return On Assets (-12.62%) which is comparable to the rest of the industry.
ABCL has a Return On Equity of -16.31%. This is in the better half of the industry: ABCL outperforms 60.71% of its industry peers.
Industry RankSector Rank
ROA -12.62%
ROE -16.31%
ROIC N/A
ROA(3y)4.03%
ROA(5y)2.91%
ROE(3y)5.04%
ROE(5y)1.61%
ROIC(3y)N/A
ROIC(5y)N/A
ABCL Yearly ROA, ROE, ROICABCL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 10 -10 -20

1.3 Margins

ABCL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABCL Yearly Profit, Operating, Gross MarginsABCL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

7

2. Health

2.1 Basic Checks

ABCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ABCL has more shares outstanding
Compared to 5 years ago, ABCL has more shares outstanding
There is no outstanding debt for ABCL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ABCL Yearly Shares OutstandingABCL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M
ABCL Yearly Total Debt VS Total AssetsABCL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

ABCL has an Altman-Z score of 1.72. This is a bad value and indicates that ABCL is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.72, ABCL is in line with its industry, outperforming 53.57% of the companies in the same industry.
There is no outstanding debt for ABCL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.72
ROIC/WACCN/A
WACC10.28%
ABCL Yearly LT Debt VS Equity VS FCFABCL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 9.34 indicates that ABCL has no problem at all paying its short term obligations.
ABCL's Current ratio of 9.34 is amongst the best of the industry. ABCL outperforms 85.71% of its industry peers.
A Quick Ratio of 9.34 indicates that ABCL has no problem at all paying its short term obligations.
ABCL has a Quick ratio of 9.34. This is amongst the best in the industry. ABCL outperforms 92.86% of its industry peers.
Industry RankSector Rank
Current Ratio 9.34
Quick Ratio 9.34
ABCL Yearly Current Assets VS Current LiabilitesABCL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

ABCL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.56%.
ABCL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -34.60%.
The Revenue has been growing by 34.00% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-35.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-70%
Revenue 1Y (TTM)-34.6%
Revenue growth 3Y-45.37%
Revenue growth 5Y34%
Sales Q2Q%-1.39%

3.2 Future

The Earnings Per Share is expected to grow by 14.64% on average over the next years. This is quite good.
The Revenue is expected to grow by 11.50% on average over the next years. This is quite good.
EPS Next Y-16.71%
EPS Next 2Y-15.37%
EPS Next 3Y-5.81%
EPS Next 5Y14.64%
Revenue Next Year-17.17%
Revenue Next 2Y6.63%
Revenue Next 3Y19.42%
Revenue Next 5Y11.5%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ABCL Yearly Revenue VS EstimatesABCL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
ABCL Yearly EPS VS EstimatesABCL Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABCL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABCL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABCL Price Earnings VS Forward Price EarningsABCL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABCL Per share dataABCL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

ABCL's earnings are expected to decrease with -5.81% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.37%
EPS Next 3Y-5.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABCL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABCELLERA BIOLOGICS INC

NASDAQ:ABCL (2/21/2025, 8:00:00 PM)

Premarket: 3.03 0 (0%)

3.03

-0.11 (-3.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners41.45%
Inst Owner Change-86.75%
Ins Owners4.17%
Ins Owner Change0.18%
Market Cap894.97M
Analysts82.67
Price Target12.39 (308.91%)
Short Float %8.26%
Short Ratio5.48
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.6%
Min EPS beat(2)-9.89%
Max EPS beat(2)11.08%
EPS beat(4)2
Avg EPS beat(4)-1.86%
Min EPS beat(4)-26.05%
Max EPS beat(4)17.44%
EPS beat(8)4
Avg EPS beat(8)-216.48%
EPS beat(12)6
Avg EPS beat(12)-137.39%
EPS beat(16)6
Avg EPS beat(16)-115.25%
Revenue beat(2)0
Avg Revenue beat(2)-24.52%
Min Revenue beat(2)-29.29%
Max Revenue beat(2)-19.76%
Revenue beat(4)1
Avg Revenue beat(4)-14.42%
Min Revenue beat(4)-29.29%
Max Revenue beat(4)1.29%
Revenue beat(8)1
Avg Revenue beat(8)-22.89%
Revenue beat(12)4
Avg Revenue beat(12)-9.45%
Revenue beat(16)6
Avg Revenue beat(16)-14.26%
PT rev (1m)-1.16%
PT rev (3m)-21.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.61%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 27.15
P/FCF N/A
P/OCF N/A
P/B 0.83
P/tB 0.92
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.11
BVpS3.65
TBVpS3.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.62%
ROE -16.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)4.03%
ROA(5y)2.91%
ROE(3y)5.04%
ROE(5y)1.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 89.97%
Cap/Sales 234.12%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.34
Quick Ratio 9.34
Altman-Z 1.72
F-Score3
WACC10.28%
ROIC/WACCN/A
Cap/Depr(3y)327.25%
Cap/Depr(5y)307.6%
Cap/Sales(3y)78.13%
Cap/Sales(5y)55.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-35.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-70%
EPS Next Y-16.71%
EPS Next 2Y-15.37%
EPS Next 3Y-5.81%
EPS Next 5Y14.64%
Revenue 1Y (TTM)-34.6%
Revenue growth 3Y-45.37%
Revenue growth 5Y34%
Sales Q2Q%-1.39%
Revenue Next Year-17.17%
Revenue Next 2Y6.63%
Revenue Next 3Y19.42%
Revenue Next 5Y11.5%
EBIT growth 1Y-47.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.03%
EBIT Next 3Y-2.49%
EBIT Next 5YN/A
FCF growth 1Y-223.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-152.3%
OCF growth 3YN/A
OCF growth 5YN/A